Geron Corporation GERN was a big mover last session, as the company saw its shares rise over 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $2.03–$2.32 in the past one-month time frame, witnessed a sharp increase yesterday.
The shares rose after the company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its experimental blood-cancer medicine, imetelstat.
The company has seen no estimate revisions over the past one month, and the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Geron currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Geron Corporation Price and Consensus
A better ranked stock in the Medical – Biomedical and Genetics industry is Axovant Sciences Ltd. AXON which also carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Is GERN going up? Or down? Predict to see what others think: Up or Down
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment